Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TSN084
i
Other names:
TSN084
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Tyligand
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TAS-115 (0)
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
regorafenib (65)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TAS-115 (0)
›
Associations
News
Trials
Filter by
Latest
5ms
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
P1, N=74, Active, not recruiting, Tyligand Bioscience (Shanghai) Limited | Recruiting --> Active, not recruiting
5 months ago
Enrollment closed • Metastases
|
TSN084
6ms
TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=114, Recruiting, Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
6 months ago
Trial completion date • Trial primary completion date • Metastases
|
TSN084
7ms
TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=114, Recruiting, Tyligand Bioscience (Shanghai) Limited
7 months ago
New P1 trial • Metastases
|
TSN084
7ms
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
P1, N=74, Recruiting, Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
7 months ago
Trial completion date • Trial primary completion date • Metastases
|
TSN084
over2years
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
P1, N=74, Recruiting, Tyligand Bioscience (Shanghai) Limited
over 2 years ago
New P1 trial
|
MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
TSN084
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login